Molecular Neurodegeneration

Article	Citations
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications	292
Alzheimer’s disease: targeting the peripheral circulation	190
Tau interactome and RNA binding proteins in neurodegenerative diseases	188
A partial Drp1 knockout improves autophagy flux independent of mitochondrial function	172
Immune cell metabolic dysfunction in Parkinson’s disease	171
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	167
Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice	167
Regulation of the hippocampal translatome by Apoer2-ICD release	156
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms	141
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	139
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	139
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	136
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	131
Positron emission tomography tracers for synucleinopathies	130
Aging-associated sensory decline and Alzheimer’s disease	128
Correction to: Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	125
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	125
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	113
AIF3 splicing switch triggers neurodegeneration	107
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	105
Correction: Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons	101
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	98
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration	95
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	92
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	86

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals	83
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	82
Pharmacological rescue of cognitive function in a mouse model of chemobrain	81
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	81
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	80
LRP1: a novel receptor for the transmission of pathological α-Synuclein	79
Glial interference: impact of type I interferon in neurodegenerative diseases	79
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	74
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	74
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	73
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023	65
TREM2 and microglia exosomes: a potential highway for pathological tau	62
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases	61
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	61
TDP-43 pathology is associated with increased tau burdens and seeding	59
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	59
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	59
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology	57
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	57
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	57
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	56
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	55
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	54
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	53
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	52
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	52
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	48
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	48
Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease	48
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	47
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	46
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	46
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	46
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice	45
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	45
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	45
Fluid biomarkers for amyotrophic lateral sclerosis: a review	45
The informed road map to prevention of Alzheimer Disease: A call to arms	44
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	43
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	43
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	42
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	42
In memoriam of Huaxi Xu, PhD, 1964–2022	41
VCP suppresses proteopathic seeding in neurons	41
α-Synuclein serine129 phosphorylation – the physiology of pathology	40
Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression	40
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	39
Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	38
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	37
Correction to: New approaches to symptomatic treatments for Alzheimer’s disease	37

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA	36
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy	35
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	35
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	34
Common mouse models of tauopathy reflect early but not late human disease	34
Rejuvenating aged microglia by p16ink4a-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer’s disease	33
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	33
One immune cell to bind them all: platelet contribution to neurodegenerative disease	32
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	32
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease	32
Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies	32
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	31
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	31
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	31
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	31
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	30
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	30
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	29
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	29
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	28
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels	28
Mechanisms of astrocyte aging in reactivity and disease	27
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	27
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	27
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	27
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	27
Collagen in the central nervous system: contributions to neurodegeneration and promise as a therapeutic target	26
Sex specific molecular networks and key drivers of Alzheimer’s disease	26
Brain clearance of protein aggregates: a close-up on astrocytes	26
Neuronal and glial vulnerability of the suprachiasmatic nucleus in tauopathies: evidence from human studies and animal models	26
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	26
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	26
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	26
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	26
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	26
Microglial lactate metabolism as a potential therapeutic target for Alzheimer’s disease	25
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	25
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	25
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	25
Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury	25
TDP-43 Pathology in Alzheimer’s Disease	24
CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration	24
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	24
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases	24
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	24
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	23
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	23
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	23
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	22
Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit?	22
NOTCH2NLC GGC intermediate repeat with serine induces hypermyelination and early Parkinson’s disease-like phenotypes in mice	22
Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS	22
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	22
Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	22
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	22
Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease	22
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s disease	21
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	21
Correction: The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	21
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	21
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging	21
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	21
Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice	20
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	20
Measuring the cognitive costs of the COVID-19 pandemic	20
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	20
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	19
The Golgi apparatus: Site for convergence of COVID-19 brain fog and Alzheimer’s disease?	19
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms	19
Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity	19
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	19
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	19
VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease	19
hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics	19
Single-domain antibody-based protein degrader for synucleinopathies	19
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	18
The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	18
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	18
Correction to: A pharmacological chaperone improves memory by reducing Aβ and tau neuropathology in a mouse model with plaques and tangles	18

Inactivation of NLRP3 inflammasome by dephosphorylation at Serine 658 alleviates glial inflammation in the mouse model of Parkinson’s disease	17
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands	17
VCP regulates early tau seed amplification via specific cofactors	17
SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer’s disease	17
The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease	16
Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies	16
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease	16
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains	16
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study	15
Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier	15
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	15
Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD	15
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms	15
LRP1 is a neuronal receptor for α-synuclein uptake and spread	15
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	14
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	14
A stress-dependent TDP-43 SUMOylation program preserves neuronal function	14
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	14
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	14
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers	14
Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease	14
APOE effects on regional tau in preclinical Alzheimer’s disease	14
Neuropathology and molecular diagnosis of Synucleinopathies	13
Opinion: more mouse models and more translation needed for ALS	13
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	13
The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease	13
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	13
Cognitive, functional, and neuropsychiatric correlates of regional tau pathology in autopsy-confirmed chronic traumatic encephalopathy	13
18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy	12
Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration	12
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients	12
Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease	12
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	12
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia	12
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	12
Donald Lowell Price, M.D. In memoriam	11
Functional microRNA targetome undergoes degeneration-induced shift in the retina	11
Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis	11
Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains	11
APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology	11
Lewy body diseases and the gut	11
Retraction Note: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	11